Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical management

Francesco Luzzaro, Gioconda Brigante, Marco Maria D'Andrea, Beatrice Pini, Tommaso Giani, Elisabetta Mantengoli, Gian Maria Rossolini, Antonio Toniolo

Research output: Contribution to journalArticle

Abstract

A remarkable increase in Proteus mirabilis strains producing acquired AmpC-type β-lactamases (CBLs) has been observed at Ospedale di Circolo e Fondazione Macchi (Varese, Italy) over the last few years. The epidemiology and treatment outcome of infections associated with this unprecedented spread are reported. From 2004-2006, 2070 P. mirabilis isolates were investigated. Extended-spectrum β-lactamases (ESBLs) and CBL resistance determinants were identified by gene amplification and direct sequencing. Clonal relatedness was evaluated by macrorestriction analysis. Overall, 43 CBL-positive isolates were obtained from hospitalised (n = 22) and non-hospitalised (n = 21) patients (median age 78.8 years). The prevalence of CBL-positive isolates increased from 0.3% in 2004 to 4.6% in 2006, whereas that of ESBL-positive isolates remained constant (ca. 10%). CBL-positive isolates were multidrug-resistant and carried the CMY-16 determinant. All but two isolates were genetically identical or closely related. Retrospective analysis of clinical records revealed that the majority of CMY-16-positive isolates were associated with urinary tract infections. Treatment with amikacin or carbapenems was consistently effective, whereas piperacillin/tazobactam produced a clinical response in seven of nine cases. This is the first report of a rapid spread of CBL-positive P. mirabilis strains endowed with remarkable antimicrobial resistance. Practical methods for CBL detection are needed for the appropriate management of related infections.

Original languageEnglish
Pages (from-to)328-333
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume33
Issue number4
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Proteus mirabilis
Epidemiology
Carbapenems
Amikacin
Gene Amplification
Infection
Urinary Tract Infections
Italy
Therapeutics

Keywords

  • Antimicrobial resistance
  • Enterobacteriaceae
  • Epidemiology
  • Outcome
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase : epidemiology and clinical management. / Luzzaro, Francesco; Brigante, Gioconda; D'Andrea, Marco Maria; Pini, Beatrice; Giani, Tommaso; Mantengoli, Elisabetta; Rossolini, Gian Maria; Toniolo, Antonio.

In: International Journal of Antimicrobial Agents, Vol. 33, No. 4, 04.2009, p. 328-333.

Research output: Contribution to journalArticle

Luzzaro, Francesco ; Brigante, Gioconda ; D'Andrea, Marco Maria ; Pini, Beatrice ; Giani, Tommaso ; Mantengoli, Elisabetta ; Rossolini, Gian Maria ; Toniolo, Antonio. / Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase : epidemiology and clinical management. In: International Journal of Antimicrobial Agents. 2009 ; Vol. 33, No. 4. pp. 328-333.
@article{a1ed1164b454446097c9bdd10ca7f330,
title = "Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical management",
abstract = "A remarkable increase in Proteus mirabilis strains producing acquired AmpC-type β-lactamases (CBLs) has been observed at Ospedale di Circolo e Fondazione Macchi (Varese, Italy) over the last few years. The epidemiology and treatment outcome of infections associated with this unprecedented spread are reported. From 2004-2006, 2070 P. mirabilis isolates were investigated. Extended-spectrum β-lactamases (ESBLs) and CBL resistance determinants were identified by gene amplification and direct sequencing. Clonal relatedness was evaluated by macrorestriction analysis. Overall, 43 CBL-positive isolates were obtained from hospitalised (n = 22) and non-hospitalised (n = 21) patients (median age 78.8 years). The prevalence of CBL-positive isolates increased from 0.3{\%} in 2004 to 4.6{\%} in 2006, whereas that of ESBL-positive isolates remained constant (ca. 10{\%}). CBL-positive isolates were multidrug-resistant and carried the CMY-16 determinant. All but two isolates were genetically identical or closely related. Retrospective analysis of clinical records revealed that the majority of CMY-16-positive isolates were associated with urinary tract infections. Treatment with amikacin or carbapenems was consistently effective, whereas piperacillin/tazobactam produced a clinical response in seven of nine cases. This is the first report of a rapid spread of CBL-positive P. mirabilis strains endowed with remarkable antimicrobial resistance. Practical methods for CBL detection are needed for the appropriate management of related infections.",
keywords = "Antimicrobial resistance, Enterobacteriaceae, Epidemiology, Outcome, Treatment",
author = "Francesco Luzzaro and Gioconda Brigante and D'Andrea, {Marco Maria} and Beatrice Pini and Tommaso Giani and Elisabetta Mantengoli and Rossolini, {Gian Maria} and Antonio Toniolo",
year = "2009",
month = "4",
doi = "10.1016/j.ijantimicag.2008.09.007",
language = "English",
volume = "33",
pages = "328--333",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase

T2 - epidemiology and clinical management

AU - Luzzaro, Francesco

AU - Brigante, Gioconda

AU - D'Andrea, Marco Maria

AU - Pini, Beatrice

AU - Giani, Tommaso

AU - Mantengoli, Elisabetta

AU - Rossolini, Gian Maria

AU - Toniolo, Antonio

PY - 2009/4

Y1 - 2009/4

N2 - A remarkable increase in Proteus mirabilis strains producing acquired AmpC-type β-lactamases (CBLs) has been observed at Ospedale di Circolo e Fondazione Macchi (Varese, Italy) over the last few years. The epidemiology and treatment outcome of infections associated with this unprecedented spread are reported. From 2004-2006, 2070 P. mirabilis isolates were investigated. Extended-spectrum β-lactamases (ESBLs) and CBL resistance determinants were identified by gene amplification and direct sequencing. Clonal relatedness was evaluated by macrorestriction analysis. Overall, 43 CBL-positive isolates were obtained from hospitalised (n = 22) and non-hospitalised (n = 21) patients (median age 78.8 years). The prevalence of CBL-positive isolates increased from 0.3% in 2004 to 4.6% in 2006, whereas that of ESBL-positive isolates remained constant (ca. 10%). CBL-positive isolates were multidrug-resistant and carried the CMY-16 determinant. All but two isolates were genetically identical or closely related. Retrospective analysis of clinical records revealed that the majority of CMY-16-positive isolates were associated with urinary tract infections. Treatment with amikacin or carbapenems was consistently effective, whereas piperacillin/tazobactam produced a clinical response in seven of nine cases. This is the first report of a rapid spread of CBL-positive P. mirabilis strains endowed with remarkable antimicrobial resistance. Practical methods for CBL detection are needed for the appropriate management of related infections.

AB - A remarkable increase in Proteus mirabilis strains producing acquired AmpC-type β-lactamases (CBLs) has been observed at Ospedale di Circolo e Fondazione Macchi (Varese, Italy) over the last few years. The epidemiology and treatment outcome of infections associated with this unprecedented spread are reported. From 2004-2006, 2070 P. mirabilis isolates were investigated. Extended-spectrum β-lactamases (ESBLs) and CBL resistance determinants were identified by gene amplification and direct sequencing. Clonal relatedness was evaluated by macrorestriction analysis. Overall, 43 CBL-positive isolates were obtained from hospitalised (n = 22) and non-hospitalised (n = 21) patients (median age 78.8 years). The prevalence of CBL-positive isolates increased from 0.3% in 2004 to 4.6% in 2006, whereas that of ESBL-positive isolates remained constant (ca. 10%). CBL-positive isolates were multidrug-resistant and carried the CMY-16 determinant. All but two isolates were genetically identical or closely related. Retrospective analysis of clinical records revealed that the majority of CMY-16-positive isolates were associated with urinary tract infections. Treatment with amikacin or carbapenems was consistently effective, whereas piperacillin/tazobactam produced a clinical response in seven of nine cases. This is the first report of a rapid spread of CBL-positive P. mirabilis strains endowed with remarkable antimicrobial resistance. Practical methods for CBL detection are needed for the appropriate management of related infections.

KW - Antimicrobial resistance

KW - Enterobacteriaceae

KW - Epidemiology

KW - Outcome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=61449240014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449240014&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.09.007

DO - 10.1016/j.ijantimicag.2008.09.007

M3 - Article

C2 - 19095415

AN - SCOPUS:61449240014

VL - 33

SP - 328

EP - 333

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -